Ocugen (OCGN) Depreciation & Amortization (CF) (2014 - 2026)
Ocugen (OCGN) reported Depreciation & Amortization (CF) of $590000.0 for Q1 2026, down 0.84% on a YoY basis from $595000.0 in Q1 2025, and up 248.61% quarter-over-quarter from -$397000.0 in Q4 2025.
Ocugen (OCGN) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
Ocugen has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $590000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 0.84% year-over-year to $590000.0; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (changed 0.0% YoY), and the FY2025 full-year result was $2.4 million, up 21.39% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $590000.0, up from -$397000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.2 million in Q2 2025, with the low at -$397000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $360647.1 across 5 years, with a median of $179000.0 in 2023.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) surged 246.33% — and 2025, when it sank 166.39%.
- Ocugen's Depreciation & Amortization (CF) stood at $173000.0 in 2022, then climbed by 3.47% to $179000.0 in 2023, then soared by 234.08% to $598000.0 in 2024, then tumbled by 166.39% to -$397000.0 in 2025, then soared by 248.61% to $590000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $590000.0 (Q1 2026), -$397000.0 (Q4 2025), and $950000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 590,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 590,000.00 |
| Mar 31, 2026 | 590,000.00 |
| Dec 31, 2025 | -397,000.00 |
| Dec 31, 2025 | -397,000.00 |
| Sep 30, 2025 | 950,000.00 |
| Sep 30, 2025 | 950,000.00 |
| Jun 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Mar 31, 2025 | 595,000.00 |
| Mar 31, 2025 | 595,000.00 |
| Dec 31, 2024 | 598,000.00 |
| Dec 31, 2024 | 598,000.00 |
| Sep 30, 2024 | 613,000.00 |
| Sep 30, 2024 | 613,000.00 |
| Jun 30, 2024 | 578,000.00 |
| Jun 30, 2024 | 578,000.00 |
| Mar 31, 2024 | 179,000.00 |
| Mar 31, 2024 | 179,000.00 |
| Dec 31, 2023 | 179,000.00 |
| Dec 31, 2023 | 179,000.00 |